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In Figure 1, as an example of the clinical-like capabilities of 
FRED, a satisfactorily comparison between the DVH obtained 
by FRED and by MCTPS [3] and a TPS commercial software is 
shown.  
  
 
Figure 5 Comparison between the DVH from Fred and ref [3] 
 
The time needed to trace the protons and optimize the dose 
is 20 s on 4x GPU NVIDA GTX 980 machine. The MC speed is 
0.33 μs/primary.  
Conclusions: The satisfactorily dosimetric agreement 
between FRED predictions and TPS/dosimetric data supports 
its future use at CNAO as fast dose recalculation tool based 
on in room patient geometry and as an independent patient 
plans verification platform.  
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In recent years, some Auger-emitting radionuclides clinically 
used for imaging/diagnostics started to be envisaged also for 
selective and targeted radiotherapy. Among the Auger-
emitting radionuclides, 125I is of particular interest, as it 
emits about 20 electrons per decay, as opposed to 4 
electrons per decay emitted by 99mTc. Nevertheless, 99mTc 
still is the most used radionuclide in diagnostic Nuclear 
Medicine; therefore, the possibility of Auger therapy with 
99mTc should open new avenues in cancer theranostics. Auger 
electrons travel a short distance within human tissues (about 
1-10 nm) and, thus, the Auger-emitting radionuclide must be 
transported to the cell nucleus to elicit DNA damage. 
Following previous encouraging results,1 we have designed 
and evaluated 99mTc(I)/Re(I) tricarbonyl complexes and 125/127I 
heteroaromatic compounds that contain an AO group for 
enhanced nuclear uptake and strong DNA intercalation. To 
have an insight on the relevance of these radiolabeled 
compounds for DNA-targeted Auger therapy we have 
investigated: i) their ability to cause DNA chain breaks; ii) 
the influence of the two different radionuclides in DNA 
damage; iii) the effect of the distance between the AO 
intercalating unit and the radioactive atom (99mTc or 125I). To 
address these issues several studies were carried out: i) 
evaluation of DNA binding and DNA damage; ii) cellular and 
nuclear internalization experiments; iii) -H2AX assays; iv) 
molecular docking and v) nanodosimetric calculations. 
Both classes of compounds are able to induce DNA double 
strand breaks (dsb) (either in plasmids or in tumor cells) but 
the extent of DNA damage (e.g. dsb yield) and the role of 
direct effects are strongly dependent on the linker used to 
attach the Auger emitting radionuclide (125I or 99mTc) to the 
AO moiety. Experimental data were corroborated by the 
docking and nanodosimetric studies; furthermore, most of 
the tested compounds presented a moderate to high uptake 
in tumor cells, with a significant accumulation in the cell 
nucleus. Altogether, these results give impetus to pursue 
with the pre-clinical evaluation of these radiolabeled AO 
derivatives as new radioactive probes for anticancer Auger 
therapy. 
 
Acknowledgements: This work was funded by FCT: projects 
EXCL/QEQ-MED/0233/2012 and UID/Multi/04349/2013, and 
FCT Investigator Grants to I Correia and F Mendes. 
 
References: 
[1]  Esteves, F. Marques, A. Paulo, J. Rino, P. Nanda, C. J. 
Smith, I. Santos, Nuclear targeting with cell-specific 
multifunctional tricarbonyl M(I) (M is Re, 99mTc) complexes: 
synthesis, characterization, and cell studies, J. Biol. Inorg. 
Chem. 16 (2011) 1141–1153. 
 
171 
The efficacy of IMRT, VMAT and IMPT to deliver highly 
conformal FET-PET guided boost in gliomas 
J.B.B. Petersen1, A.I.S. Holm1, K. Seiersen1, P. Borghammer2, 
S. Lukacova3 
1Department of Medical Physics, Aarhus University Hospital, 
Aarhus, Denmark 
2Department of Nuclear Medicine & PET Centre, Aarhus 
University Hospital, Aarhus, Denmark 
3Department of Oncology, Aarhus University Hospital, Aarhus, 
Denmark 
 
Purpose: Radiotherapy plays an important role in treatment 
of gliomas even though the clinical outcome is relatively 
poor, mainly due to local failure. A higher uniform tumour 
dose may however increase the risk of adverse effects, 
especially for lager target volumes. 
A selective boost to the 18F-fluoro-ethyl-tyrosine (FET)-PET 
active volume, might prolong time to progression without 
increasing the risk of adverse effects. The present treatment 
planning study investigate and compare the ability of three 
techniques, VMAT, IMRT and IMPT to deliver a high conformal 
high dose boost to the BTV in patients with gliomas. 
Material/methods: Seven patients with a pre therapeutic 
FET-PET/CT and MRI were used in the study.  
For each patient a standard IMRT treatment plan giving 60 Gy 
in 30 fractions to the BTV and 46 Gy to the CTV(46 Gy) was 
calculated as a benchmark. A CTV(46 Gy) was defined as 
tumor and/or tumor cavity added a 2 cm margin. The BTV 
was defined from the FET PET and covered a tumor-to-brain 
cut-off ratio of FET uptake ≥ 1.6 (pre-surgery) and ≥ 2.1 
(post-surgery). Both BTV and CTV(46 Gy) were modified to 
respect anatomic barriers. Planning target volumes (PTV), 
PTV(boost) and PTV(46 Gy) were generated by uniformly 
expanding the BTV and CTV(46 Gy), respectively with 3mm. 
The standard IMRT plans were used to define the base level 
of dose to the organs at risk (OAR) and PTV(46 Gy) 
homogeneity. To evaluate the dose to the OAR the mean 
dose was used. The PTV(46 Gy) homogeneity was defined as 
the volume of PTV(46 Gy) subtracted PTV boost which 
received more than 107% of the prescribed 46 Gy. The IMRT, 
VMAT and IMPT dose escalating treatment plans were 
optimized in order to get the highest achievable mean PTV 
boost dose, without increasing the mean dose to critical OAR 
and without decreasing the PTV(46 Gy) homogeneity. For all 
plans the dose boost was given as the integrated boost over 
30 fractions. All treatment plans were carried out using the 
Eclipse treatment planning system (Varian Medical systems, 
Palo Alto, CA, USA). 
Results: A standard IMRT plans were calculated for all 
patients and the base level for PTV(46 Gy) homogeneity was 
found to range between 65 % to 86 %, with a median value of 
77%. Dose escalating, while maintaining this homogeneity, 
was found feasible using all three techniques.  The mean 
doses to PTV(boost) were 77.1Gy, 79,2Gy and 85.1Gy for 
